Fine-Tuning the Treatment Algorithm in Adv H&N Cancer

Fine-Tuning the Treatment Algorithm in Adv H&N Cancer

Not a member of My prIME? Join now for instant access.

Shuttle buses from the IFEMA congress center to Palacio Neptuno will be provided by prIME Oncology and not the commercial supporter of this program. Further details will follow.

Meeting Overview

Engage with experts in the field of advanced head and neck cancer by joining this highly interactive, clinical case-based evening meeting. You will gain expert insights on a multidisciplinary approach for managing HPV+ and HPV- locally advanced head and neck squamous cell cancer (HNSCC). Furthermore, expand your knowledge on treatment options for patients with advanced HNSCC, including combinations of conventional therapies and immunotherapies. Attendees will have the opportunity to interact with the expert faculty throughout the meeting.

Date and Location

Sunday, 10 September 2017
18.30 – 19.00 Registration and Dinner
19.00 – 20.30 Educational Session

Palacio Neptuno
Venus Room
Calle Cervantes, 42
Madrid, Spain



Sunday, 10 September 2017



Madrid, Spain



1.5 AMA PRA Category 1 Credits

18.30 Registration and dinner
19.00 Welcome and clinical scenario questions
Jan Vermorken, MD, PhD
19.05 The evolving treatment algorithm for advanced HNSCC
Jan Vermorken, MD, PhD
19.15 Scenario #1—Locally advanced HNSCC: What are the options for cisplatin ineligible patients?
Lisa Licitra, MD, PhD
19.35 Faculty panel & audience discussion
19.40 Scenario #2—Recurrent/metastatic HNSCC: Front-line therapy and beyond
Ana Castro, MD
20.00 Faculty panel & audience discussion
20.05 Scenario #3—Progression on immunotherapy in recurrent/metastatic HNSCC
Amanda Psyrri, MD, PhD
20.25 Faculty panel & audience discussion
20.30 prIME Points™
Jan Vermorken, MD, PhD


  • Jan Vermorken, MD, PhDAntwerp University Hospital
    Antwerp, Belgium

  • Ana Castro, MDCentro Hospitalar do Porto
    Porto, Portugal
  • Lisa Licitra, MD, PhDFondazione IRCCS - Istituto Nazionale dei Tumori
    Milan, Italy
  • Amanda Psyrri, MD, PhDNational and Kapodistrian University of Athens
    Attikon University Hospital
    Athens, Greece

This educational activity is specifically designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals involved in the treatment of patients with head and neck cancer.

After successful completion of this educational activity, participants should be able to:

  • Explain multidisciplinary approaches for managing HPV+ and HPV- locally advanced HNSCC
  • Select optimal treatment sequence for patients with recurrent/metastatic HNSCC
  • Evaluate therapeutic options for advanced HNSCC after progression on immunotherapy and identify ongoing research strategies in advanced HNSCC, including combinations of conventional therapies and immunotherapies

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



This activity is provided by prIME Oncology.


prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.